The Applications of Targeting Anti-Cancer Agents in Cancer Therapeutics

Area of Science:

• Oncology
• Pharmacology

Background:

• Targeted anti-cancer drugs represent a significant advancement over traditional chemotherapy.
• These drugs target specific molecules over-expressed or aberrantly expressed in cancer cells.
• Tumor angiogenesis and tyrosine kinase mutations are critical in cancer progression.

Purpose of the Study:

• To review advances in targeted anti-cancer drug development.
• Focus on small molecule tyrosine kinase inhibitors, monoclonal antibodies against ErbB receptors, and angiogenic inhibitors.
• To address challenges of drug resistance and adverse events.

Main Methods:

• Literature review of targeted anti-cancer therapies.
• Focus on small molecule tyrosine kinase inhibitors.
• Review of monoclonal antibodies targeting epidermal growth factor receptors (ErbB family).
• Examination of angiogenic inhibitors.
• Discussion of drug resistance mechanisms and adverse events.

Main Results:

• Targeted therapies offer improved specificity, efficacy, and reduced side effects compared to traditional chemotherapy.
• Small molecule tyrosine kinase inhibitors, monoclonal antibodies, and angiogenic inhibitors are key classes of targeted drugs.
• Drug resistance and adverse events remain significant concerns requiring further research and management strategies.

Conclusions:

• Targeted therapy is a revolutionary approach in cancer treatment.
• Continued research into novel targeted agents and strategies to overcome resistance is crucial.
• Managing adverse events is essential for optimizing patient outcomes with targeted therapies.